ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO684

Regulatory Function of FcγRIIB Involving the NLRP3 Inflammasome in a Mouse Model of IgA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1401 Glomerular Diseases: From Inflammation to Fibrosis


  • Chen, Ann, Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
  • Chou, Yu-Ling, National Defense Medical Center, Taipei, Taiwan
  • Ka, Shuk-Man, National Defense Medical Center, Taipei, Taiwan

IgA nephropathy (IgAN) is the most common form of glomerulonephritis and represents a leading cause of end-stage renal disease. Ample evidence confirms the deposition of IgA and IgG and filtration of mononuclear leukocytes in IgAN patients. Previously, we established an experimental IgAN model in B cell-deficient mice, which implicated interactions between Fcγ receptors (FcγRs) in the pathogenesis of IgAN. Although it is generally accepted that FcγRIIB plays a regulatory role in humoral responses, it remains unknown whether this function and the cell type-specificity of FcγRIIB are reno-protective in IgAN.


We observed a dramatic increase in albuminuria, renal function impairment, and renal injury in FcγRIIB knockout mice with induced IgAN. Utilizing a mouse model of IgAN and three different types of FcγRIIB-deficient mice, including CEBP/α Cre (myeloid cells), CD11c Cre (dendritic cells) and CD19 Cre (B cells) in floxed FcγRIIB mice, as well as several specific cell models.


We demonstrated that macrophage- and dendritic cell-specific FcγRIIB deficiency blunted the activation of the NLRP3 inflammasome and inhibited the development of IgAN. Moreover, activation of the inflammasome was induced by IgA immune complexes dependent on TLR4/MyD88 signaling, associated with crosstalk between TLR4 and Dectin-2.


These results suggest that activation of FcγRIIB and its downstream signaling pathways could moderate progression of IgAN involving the suppression of the NLRP3 inflammasome. A cell type-specific targeting of FcγRIIB may help the establishment of therapeutic strategy for the renal disease.